Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $29.75.

A number of brokerages recently commented on JSPR. JMP Securities dropped their price target on Jasper Therapeutics from $70.00 to $12.00 and set a “market outperform” rating on the stock in a report on Tuesday, July 8th. Cantor Fitzgerald lowered Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, July 7th. Evercore ISI cut their price target on shares of Jasper Therapeutics from $50.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. UBS Group decreased their price objective on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Finally, BTIG Research dropped their target price on shares of Jasper Therapeutics from $64.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 7th.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $3.15 on Friday. The firm has a 50-day moving average of $4.88 and a 200-day moving average of $5.10. Jasper Therapeutics has a one year low of $2.27 and a one year high of $26.05. The company has a market cap of $47.32 million, a P/E ratio of -0.60 and a beta of 2.69.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). As a group, research analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in shares of Jasper Therapeutics by 13.9% in the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock worth $579,000 after buying an additional 3,310 shares in the last quarter. Deutsche Bank AG lifted its stake in Jasper Therapeutics by 30.0% in the 4th quarter. Deutsche Bank AG now owns 170,695 shares of the company’s stock worth $3,649,000 after purchasing an additional 39,436 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the period. Simplify Asset Management Inc. bought a new position in Jasper Therapeutics in the 4th quarter valued at $428,000. Finally, Soleus Capital Management L.P. grew its position in shares of Jasper Therapeutics by 11.2% during the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after purchasing an additional 150,755 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.